卵巢癌血管靶向治疗的研发与应用
血管靶向治疗(VTT)包括抗血管生成药物(AA)和血管破坏剂(VDA),是铂耐药复发性卵巢癌(OC)有前景的治疗策略。贝伐珠单抗联合化疗可改善晚期OC无进展生存期(PFS)。CA4P是唯一在OC中积极开发的VDA,II期试验显示CA4P联合贝伐珠单抗较贝伐珠单抗单药改善PFS;PAZOFOS和FOCUS试验正在评估含CA4P方案的疗效。
要点
- VTT分为抗血管生成药物和血管破坏剂两类,机制不同。
- 贝伐珠单抗联合化疗可改善晚期OC的PFS。
- CA4P联合贝伐珠单抗在复发性OC的II期试验中改善PFS。
核心结论
- 血管靶向治疗是铂耐药复发性卵巢癌有前景的治疗方向,VDA与化疗及AA联合可能增强疗效。
研究设计与样本
- 综述性文章,汇总VTT在卵巢癌中的研发与临床试验证据。
主要发现
- 贝伐珠单抗联合化疗可改善晚期OC患者的PFS。
- CA4P联合贝伐珠单抗在复发性OC的II期试验中较贝伐珠单抗单药改善PFS。
- 动物研究和临床试验显示VDA与化疗或AA联合时疗效增强。
关键数值与推荐
- CA4P是唯一在OC中积极开发的VDA。
- PAZOFOS(NCT02055690)为II期安慰剂对照试验,评估CA4P联合帕唑帕尼治疗复发性OC。
- FOCUS(NCT02641639)为II/III期安慰剂对照试验,评估CA4P联合贝伐珠单抗及化疗治疗铂耐药OC。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Combination vascular-targeted therapies (VTTs) represent a promising approach for patients with platinum-resistant recurrent ovarian cancer (OC). VTTs include two mechanistically distinct classes of agents: anti-angiogenic agents (AAs) and vascular-disrupting agents (VDAs). AAs suppress growth of new tumor vasculature through inhibition of vascular endothelial growth factor (VEGF) and other pro-angiogenic molecules. Bevacizumab, a monoclonal antibody that binds to VEGF, has improved progression-free survival (PFS) when given with chemotherapy in patients with advanced OC. VDAs target the established tumor vascular network, inducing vessel occlusion, shutdown of circulation, and widespread necrosis within the tumor interior - a region often resistant to conventional chemotherapy and radiation. Tubulin-binding VDAs such as BNC105P, ombrabulin, and combretastatin A4-phosphate (CA4P) have been studied for the treatment of OC. These agents act by binding tubulin in the endothelial cells of tumor vessels, triggering cytoskeletal disruption, altering cellular shape, and destabilizing cell-cell junctions, which lead to increased vascular leakage and, ultimately, to disruption of blood flow. Fundamental differences between the vascular networks of tumors and those of normal tissues allow these agents to selectively reduce tumor circulation while having little effect on non-malignant tissues. Animal studies and clinical trials show enhanced efficacy when VDAs are combined with chemotherapy as well as AAs. The latter combination allows targeting of different aspects of the tumor vasculature, a strong rationale for combining these two drug classes into a single regimen. CA4P is the only VDA in active development for OC. In a phase II trial of patients with recurrent OC, CA4P added to bevacizumab improved PFS compared with bevacizumab alone. The phase II, placebo-controlled PAZOFOS trial (NCT02055690) is evaluating the effects of CA4P plus the anti-angiogenic agent pazopanib in recurrent OC. FOCUS, a phase II/III, placebo-controlled trial (NCT02641639), is currently evaluating CA4P plus bevacizumab and chemotherapy in platinum-resistant OC.
引用
- Chase DM, Chaplin DJ, Monk BJ, et al. The development and use of vascular targeted therapy in ovarian cancer. Gynecol Oncol. 2017. PMID: 28238563. doi:10.1016/j.ygyno.2017.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。